This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Threshold Pharmaceuticals Reports Second Quarter 2011 Financial And Operational Results

Threshold Pharmaceuticals, Inc. (Nasdaq:THLD), today reported financial results for the second quarter ended June 30, 2011. The net loss for the second quarter and six months ended June 30, 2011 was $7.9 million and $16.3 million, respectively. As of June 30, 2011, Threshold had $31.5 million in cash, cash equivalents and marketable securities, with no debt outstanding.

The net loss for the second quarter of 2011 was $7.9 million compared to $0.3 million for the second quarter of 2010. Included in the net loss, for second quarter of 2011 was non-cash expense of $1.2 million compared to non-cash income of $5.7 million in the second quarter of 2010. The non-cash income (expense) was related to the changes in fair value of the Company’s outstanding warrants and was classified as other income (expense). Research and development expenses were $5.1 million for the second quarter of 2011 compared to $5.0 million for the second quarter of 2010. The increase in research and development expenses primarily reflects an increase in clinical trial expenses related to TH-302. General and administrative expenses were $1.7 million for the second quarter of 2011 versus $1.0 million for the second quarter of 2010. The increase in general and administrative expenses was primarily due to an increase in consulting, facilities and personnel related expenses. Non-cash stock compensation expense for the Company was $0.2 million for the second quarter of 2011 versus $0.2 million for the second quarter of 2010.

For the six months ended June 30, 2011, the net loss was $16.3 million, compared to $6.2 million for the six months ended June 30, 2010. Included in the net loss, for the six months ended June 30, 2011 was non-cash expense of $2.1 million compared to non-cash income of $5.5 million for the six months ended June 30, 2010. The non-cash income (expense) was related to the changes in fair value of the Company’s outstanding warrants and was classified as other income (expense). Research and development expenses were $11.2 million in the first half of 2011 compared to $9.4 million in the first half of 2010, and increased primarily due to clinical trial expenses related to TH-302. General and administrative expenses increased to $3.0 million in the first half of 2011 from $2.3 million in the first half of 2010, primarily due to an increase in consulting, facilities and personnel related expenses. Total non-cash stock compensation expense for the Company was $0.5 million for the first half of 2011 versus $0.3 million for the first half of 2010. This increase was primarily due to the amortization of an increased number of options.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,024.06 +183.54 1.03%
S&P 500 2,108.29 +22.78 1.09%
NASDAQ 5,005.3910 +63.9670 1.29%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs